Description
Seeking people aged 12 to 85 years old with GuillainBarré Syndrome who experience muscle weakness and who have not been treated with plasma exchange or IV immunoglobulin for a study of an investigational drug.
Overview
Participants in this study will receive one infusion with the investigational drug that may take up to 18 hours. There will be a hospital stay of up to 8 days during and following the infusion to ensure the safety of the participants. Then there will be follow-up study visits one week, two weeks, four weeks, 8 weeks and 6 months after the infusion.
What we're hoping for
We are studying whether an investigational monoclonal antibody infusion is safe and effective in preventing the immune system from attacking their own body’s nerve cells for people aged 12 to 85 with Guillain Barré Syndrome .
Additional Information
ClinicalTrials.gov Identifier: NCT07020819